Press Release FeedGet the RSS feed
Menu

Business Wire

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Bristol-Myers Squibb

CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus's largest licensors of de-identified oncology data.

Additionally, BMS will gain access to Tempus' Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world's largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train and execute advanced AI models using de-identified data to surface breakthroughs faster and increase the probability of technical success when developing candidate therapies at scale.

This agreement expands upon the long-standing strategic relationship between Tempus and BMS, which includes applying AI and multimodal real-world data to optimize clinical trial design across high-priority oncology programs and neuroscience initiatives.

"This strategic collaboration is an important step forward in using AI to advance the discovery of new treatment options and potentially improve patient outcomes," said Eric Lefkofsky, Founder and CEO of Tempus. "By uniting our vast multimodal data asset with dedicated GPU power inside our Lens Platform, we are equipping BMS with the AI tools necessary to decode complex biology. Together, we aren't just speeding up drug discovery, we are laying the foundation for a future where precision oncology becomes the standard of care for every patient."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

  1. FinanceBristol Myers SquibbBristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Companies: Bristol-Myers SquibbData reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis PRINCETON, N.J., October 23, 2026--Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohort
  2. AIPathos AIPathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological ConditionsCompanies: Bristol-Myers SquibbTempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos's AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb's (BMS) neuroscience drug development expertise to b
  3. HealthcareThe Institute for Healthcare ImprovementIHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical TrialsCompanies: Bristol-Myers SquibbThree-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON, October 22, 2026--The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This thr
  4. Bristol Myers SquibbBristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026Companies: Bristol-Myers SquibbLate-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01) Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific i
  5. HealthcareBristol Myers SquibbOn the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' InitiativeCompanies: Bristol-Myers SquibbReinforcing its commitment to putting patients at the centre of everything it does, Bristol Myers Squibb (BMS), a leading global biopharmaceutical...
  6. HealthcareBristol Myers SquibbOn the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' InitiativeCompanies: Bristol-Myers SquibbMore than 70 personalized 'Small Wins' toolkits, assembled by Bristol Myers Squibb employees, were designed to encourage everyday engagement, self-recognition and emotional well-being among people living with schizophrenia in Saudi Arabia. RIYADH, Saudi Arabia, Oct. 12, 2026...